Skip to content

Effects of Long Term Calorie Restriction on Sphingomyelin and Amino Acids

Three-year Mild Calorie Restriction Partially Protects Against Age-related Increase in Sphingomyelin and Reduces Obesity-associated Amino Acids

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02081898
Enrollment
120
Registered
2014-03-07
Start date
2010-06-30
Completion date
2010-08-31
Last updated
2014-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight, Obese

Keywords

low calorie diet, BMI, sphingomyelin, L-leucine, L-phenylalanine

Brief summary

The effect of weight loss with long-term low calorie diet (LCD) on plasma metabolites is unknown. The aim was to examine whether a LCD-induced weight reduction results in changes in the extended plasma metabolites.

Detailed description

Overweight/obese subjects (25≤ BMI \<33 kg/m2) aged 40 to 59 years consumed a LCD (an approximate 100 kcal/day calorie deficit) or a weight-maintenance diet (control) in a randomized, controlled design with 3-year intervention period.

Interventions

DIETARY_SUPPLEMENTLCD

approximate 100 kcal/d caloric deficit

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 59 Years
Healthy volunteers
No

Inclusion criteria

* 25 \<= BMI \< 33 kg/m2

Exclusion criteria

* type 2 diabetes * cardiovascular disease * psychiatric problems * any medication use

Design outcomes

Primary

MeasureTime frameDescription
anthropometry3-year follow-upweight, height, BMI, waist circumference, blood pressure

Secondary

MeasureTime frameDescription
biochemistry analysis3-year follow-uptotal-cholesterol, LDL-cholesterol, HDL-cholesterol, triglyceride, free fatty acids, glucose, insulin, HOMA-IR, Lp-PLA2

Other

MeasureTime frameDescription
plasma metabolites3-year follow-uppalmitic amide, oleamide, lysoPC (16:1, 16:0, 17:0, 18:2, 18:1, 18:0, 20:4, 20:3, 22:6), PC (16:0/20:5, 16:0/20:5, 18:2/18:2, 18:0/20:4), lactosylceramide (d18:1/12:2)

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026